Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I clinical trial of SNDX-5613 in patients with a defined subset of acute leukemias

Trial Profile

A phase I clinical trial of SNDX-5613 in patients with a defined subset of acute leukemias

Planning
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs SNDX 5613 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Nov 2018 New trial record
    • 05 Nov 2018 According to a Syndax Pharmaceuticals media release, the company expects to file an investigational new drug application (IND) with the FDA and initiate the trial in the second quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top